<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852265</url>
  </required_header>
  <id_info>
    <org_study_id>890433</org_study_id>
    <nct_id>NCT02852265</nct_id>
  </id_info>
  <brief_title>Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study</brief_title>
  <acronym>NexTOC</acronym>
  <official_title>Nexplanon Use in Women Primarily Choosing a Combined Hormonal Contraceptive: a Proof of Concept Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women currently using or starting a combined oral contraceptive will be offered study
      enrollment. Study subjects will have a Nexplanon placed and followed for 6 months to evaluate
      if they continue the COC, continue the implant, or both, and to assess adverse events and
      bleeding patterns.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will recruit women being seen in a UC Davis medical office or who contact
      our research office. Potential participants must be women currently COCs or intending to
      initiate COCs at the time of the office visit. The investigators expect that most women will
      be recruited while in the office who decide to initiate COCs or are continuing COC useâ€”these
      women will be offered the ability to talk to research staff about the study.

      Visit 1:

      Informed consent will be obtained. As part of informed consent, subjects will be educated
      that there is little data available on the adverse effects of combined COC and ENG implant
      use. The consent form will include a standardized description of the side effects and
      bleeding profile of COCs and the implant. Subjects will also need to review the package label
      information for Nexplanon and sign the FDA-required Nexplanon consent. After obtaining
      informed consent, subjects will be screened for entry criteria. Medical history will be
      obtained. A urine pregnancy test will be performed. Eligible subjects will receive a
      prescription for the desired COC (if needed) and have a Nexplanon contraceptive implant
      placed. A diary will be dispensed for the subject to document daily bleeding, COC use and
      adverse events.

      Follow-up A follow-up visit will occur at 1 month (+1 week) and 3 and 6 months (+2 weeks).
      The diary will be reviewed and a copy made to keep with the source documentation. Adverse
      events will be determined by inquiry and diary review. The subject will inform the study
      staff if she is using her COC and if she wants to continue use of her COC and ENG implant. At
      the 1 and 3 month visits, additional diaries will be dispensed as needed. The ENG implant
      will be removed upon request at any time during the study.

      A phone call will occur approximately 1 week prior to the 3 and 6 month visits to check
      status and remind subject of the scheduled visit. Study participation will be complete after
      the 6 month follow-up visit.

      No surveys will be used that the subject fills out herself. A daily diary will be used.

      No blood draws will occur during this study.

      Data to be collected by study staff include demographics, past medical and gynecologic
      history, prior and current contraceptive use, and reason for using COC (contraception,
      medical or both).

      Because women are being enrolled who are already currently using COCs or who plan to start
      COCs, the COC is not a study drug. The study intervention (study drug) is the contraceptive
      implant. The systemic hormone exposure with a contraceptive implant is minimal relative to a
      COC. We would not expect any increase in side effects by adding a contraceptive implant to
      COC users. Of note, the primary risk with COC use is related to the estrogen which can
      increase the risk of venous thromboembolic disease. The implant has no estrogen. All products
      being used in the study are FDA-approved for contraception.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2016</start_date>
  <completion_date type="Actual">July 26, 2017</completion_date>
  <primary_completion_date type="Actual">July 26, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Evaluating ENG as Acceptable: Acceptability (Measurement: Questionnaire)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the acceptability (continuation of the implant throughout the study) of concomitant etonogestrel (ENG) implant use in women choosing a combined oral contraceptive (COC) for contraception</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Evaluating ENG as Tolerable: Tolerability (Measurement: Diaries and Questionnaire)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the tolerability (side effects) of concomitant etonogestrel (ENG) implant use in women choosing a combined oral contraceptive (COC) for contraception</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Interest (Measurement: Ability to Enroll)</measure>
    <time_frame>6 months</time_frame>
    <description>Demonstrate that women desiring a COC are willing to use ENG implant concomitantly as a continuous &quot;back-up&quot; contraceptive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns (Measurement: Diaries)</measure>
    <time_frame>6 months</time_frame>
    <description>Bleeding patterns while using a COC concomitantly with ENG implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COC Continuation Rate (Measurement: Participant Interview)</measure>
    <time_frame>6 months</time_frame>
    <description>Continuation rate of COC over 6 months of evaluation regardless on whether or not the implant was still present at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-study Method Plan (Measurement: Participant Interview)</measure>
    <time_frame>6 months</time_frame>
    <description>Plan to continue the COC and/or implant after the study based on interview at last visit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>COC users or new starts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women starting a COC or recently started a COC within the past month will be considered new starts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel contraceptive implant</intervention_name>
    <description>Place nexplanon</description>
    <arm_group_label>COC users or new starts</arm_group_label>
    <other_name>Nexplanon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Women being seen in a UC Davis medical office or who contact our research office.

          -  Potential participants must be women currently COCs or intending to initiate COCs at
             the time of the office visit.

        Exclusion:

          -  Women who have contraindications to using a COC or a contraceptive implant (Category 3
             or 4 in the CDC Medical Eligibility Criteria) will be excluded.

          -  Adults unable to consent

          -  Individuals who are not yet adults (infants, children, teenagers)

          -  Pregnant women

          -  Prisoners
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Creinin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <results_first_submitted>March 27, 2018</results_first_submitted>
  <results_first_submitted_qc>June 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2018</results_first_posted>
  <last_update_submitted>December 6, 2018</last_update_submitted>
  <last_update_submitted_qc>December 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral contraceptive</keyword>
  <keyword>contraceptive implant</keyword>
  <keyword>contraception</keyword>
  <keyword>adherence</keyword>
  <keyword>adverse event</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02852265/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We consented and enrolled 20 women in the outpatient clinic at the University of California, Davis Department of Obstetrics and Gynecology for study participation between September and December 2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>New Start COC Users</title>
          <description>Women who are starting or recently started (within last 4 weeks) a combined oral contraceptive</description>
        </group>
        <group group_id="P2">
          <title>Continuing COC Users</title>
          <description>Women who have been using a combined oral contraceptive for more than 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>1-month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>3-month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>6-month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>New Start COC Starters</title>
          <description>Women who are starting or recently started (within last 4 weeks) a combined oral contraceptive</description>
        </group>
        <group group_id="B2">
          <title>Continuing COC Users</title>
          <description>Women who have been using a combined oral contraceptive for more than 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="20" upper_limit="34"/>
                    <measurement group_id="B2" value="20.5" lower_limit="16" upper_limit="34"/>
                    <measurement group_id="B3" value="23" lower_limit="16" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pill type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>21/7 monophasic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>24/4 monophasic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>21/7 triphasic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Continuous dosing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Evaluating ENG as Acceptable: Acceptability (Measurement: Questionnaire)</title>
        <description>Evaluate the acceptability (continuation of the implant throughout the study) of concomitant etonogestrel (ENG) implant use in women choosing a combined oral contraceptive (COC) for contraception</description>
        <time_frame>6 months</time_frame>
        <population>All women enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>New Start COC Users</title>
            <description>Women who are starting or recently started (within last 4 weeks) a combined oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Continuing COC Users</title>
            <description>Women who have been using a combined oral contraceptive for more than 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Evaluating ENG as Acceptable: Acceptability (Measurement: Questionnaire)</title>
          <description>Evaluate the acceptability (continuation of the implant throughout the study) of concomitant etonogestrel (ENG) implant use in women choosing a combined oral contraceptive (COC) for contraception</description>
          <population>All women enrolled in study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Evaluating ENG as Tolerable: Tolerability (Measurement: Diaries and Questionnaire)</title>
        <description>Evaluate the tolerability (side effects) of concomitant etonogestrel (ENG) implant use in women choosing a combined oral contraceptive (COC) for contraception</description>
        <time_frame>6 months</time_frame>
        <population>All enrolled subjects, new or worsening side effects after 6 months of use in women using both an implant and a COC</population>
        <group_list>
          <group group_id="O1">
            <title>New Start COC Users</title>
            <description>Women who are starting or recently started (within last 4 weeks) a combined oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Continuing COC Users</title>
            <description>Women who have been using a combined oral contraceptive for more than 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Evaluating ENG as Tolerable: Tolerability (Measurement: Diaries and Questionnaire)</title>
          <description>Evaluate the tolerability (side effects) of concomitant etonogestrel (ENG) implant use in women choosing a combined oral contraceptive (COC) for contraception</description>
          <population>All enrolled subjects, new or worsening side effects after 6 months of use in women using both an implant and a COC</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mastalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mood complaints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worsening acne</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worsening dysmenorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>weight gain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Interest (Measurement: Ability to Enroll)</title>
        <description>Demonstrate that women desiring a COC are willing to use ENG implant concomitantly as a continuous &quot;back-up&quot; contraceptive</description>
        <time_frame>6 months</time_frame>
        <population>women using or starting a COC and having an etonogestrel implant placed; 1 lost to follow-up in each group from enrollment (n=10 in both groups at enrollment)</population>
        <group_list>
          <group group_id="O1">
            <title>COC Users</title>
            <description>Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users.</description>
          </group>
          <group group_id="O2">
            <title>COC New Starts</title>
            <description>Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women starting a COC or recently started a COC within the past month will be considered new starts.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Interest (Measurement: Ability to Enroll)</title>
          <description>Demonstrate that women desiring a COC are willing to use ENG implant concomitantly as a continuous &quot;back-up&quot; contraceptive</description>
          <population>women using or starting a COC and having an etonogestrel implant placed; 1 lost to follow-up in each group from enrollment (n=10 in both groups at enrollment)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns (Measurement: Diaries)</title>
        <description>Bleeding patterns while using a COC concomitantly with ENG implant</description>
        <time_frame>6 months</time_frame>
        <population>women using or starting a COC and having an etonogestrel implant placed; 1 lost to follow-up in each group from enrollment (n=10 in both groups at enrollment)</population>
        <group_list>
          <group group_id="O1">
            <title>COC Users</title>
            <description>Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users.
Etonogestrel contraceptive implant: Place nexplanon</description>
          </group>
          <group group_id="O2">
            <title>New Starts</title>
            <description>Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women starting a COC or recently started a COC within the past month will be considered new starts.
Etonogestrel contraceptive implant: Place nexplanon</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns (Measurement: Diaries)</title>
          <description>Bleeding patterns while using a COC concomitantly with ENG implant</description>
          <population>women using or starting a COC and having an etonogestrel implant placed; 1 lost to follow-up in each group from enrollment (n=10 in both groups at enrollment)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>prolonged 1st 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>frequent 1st 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>irregular 1st 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>infrequent 1st 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>amenorrhea 1st 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>regular 1st 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>prolonged 2nd 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>frequent 2nd 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>irregular 2nd 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>infrequent 2nd 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>amenorrhea 2nd 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>regular 2nd 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COC Continuation Rate (Measurement: Participant Interview)</title>
        <description>Continuation rate of COC over 6 months of evaluation regardless on whether or not the implant was still present at 6 months</description>
        <time_frame>6 months</time_frame>
        <population>women using or starting a COC and having an etonogestrel implant placed; 1 lost to follow-up in each group from enrollment (n=10 in both groups at enrollment)</population>
        <group_list>
          <group group_id="O1">
            <title>COC Users</title>
            <description>Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users.
Etonogestrel contraceptive implant: Place nexplanon</description>
          </group>
          <group group_id="O2">
            <title>New Starts</title>
            <description>Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women starting a COC or recently started a COC within the past month will be considered new starts.
Etonogestrel contraceptive implant: Place nexplanon</description>
          </group>
        </group_list>
        <measure>
          <title>COC Continuation Rate (Measurement: Participant Interview)</title>
          <description>Continuation rate of COC over 6 months of evaluation regardless on whether or not the implant was still present at 6 months</description>
          <population>women using or starting a COC and having an etonogestrel implant placed; 1 lost to follow-up in each group from enrollment (n=10 in both groups at enrollment)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-study Method Plan (Measurement: Participant Interview)</title>
        <description>Plan to continue the COC and/or implant after the study based on interview at last visit</description>
        <time_frame>6 months</time_frame>
        <population>women using or starting a COC and having an etonogestrel implant placed; 1 lost to follow-up in each group from enrollment (n=10 in both groups at enrollment)</population>
        <group_list>
          <group group_id="O1">
            <title>COC Users</title>
            <description>Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users.
Etonogestrel contraceptive implant: Place nexplanon</description>
          </group>
          <group group_id="O2">
            <title>New Starts</title>
            <description>Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women starting a COC or recently started a COC within the past month will be considered new starts.
Etonogestrel contraceptive implant: Place nexplanon</description>
          </group>
        </group_list>
        <measure>
          <title>Post-study Method Plan (Measurement: Participant Interview)</title>
          <description>Plan to continue the COC and/or implant after the study based on interview at last visit</description>
          <population>women using or starting a COC and having an etonogestrel implant placed; 1 lost to follow-up in each group from enrollment (n=10 in both groups at enrollment)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>using implant only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>using COC only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>using implant and COC</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>not using implant or COC</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months of follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>New Start COC Users</title>
          <description>Women who are starting or recently started (within last 4 weeks) a combined oral contraceptive</description>
        </group>
        <group group_id="E2">
          <title>Continuing COC Users</title>
          <description>Women who have been using a combined oral contraceptive for more than 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Nexplanon removal</sub_title>
                <description>removal of implant</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Melissa Chen</name_or_title>
      <organization>University of California, Davis</organization>
      <phone>916-734-6670</phone>
      <email>mejchen@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

